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a-l-Fetoprotein (AFP) was measured in the sera of 5 hepatoma pa-
tients following total hepatectomy and orthotopic liver transplantation. 
Immunosuppressive therapy, rejection episodes, and infection did not 
alter the serum level of AFP. Low AFP levels persisting posttransplan-
tation indicated the presence of slow-growing residual tumor in 3 pa-
tients. A sharp increase in serum AFP levels preceded clinical evidence 
of rapid tumor growth in 1 patient. Disappearance of AFP in 1 patient 
who is still symptom-free after 9 months suggests little or no residual 
tumor. Serial AFP levels can be helpful in assessing the results of thera-
peutic attempts in patients with liver carcinoma. 
Human a-fetoprotein (AFP) is a unique 
fetal a-I globulin which reappears in the 
serum of most patients with carcinoma of 
the liver and has been shown to be diag-
nostic of this malignancy in the adult. 1-5 
The serum concentration of AFP has been 
found to stabilize or generally increase with 
progression and growth of the tumor. 4, 6 
In this study we have examined the changes 
in the serum concentration of AFP after 
autologous liver transplantation in 5 pa-
tients with hepatoma in an effort to assess 
the value of AFP in predicting tumor 
residual or recurrence. 
Methods 
Monospecific antisera to AFP were raised 
in rabbits according to previously pub-
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lished methods and shown to be mono-
specific by double immunodiffusion, immuno-
electrophoresis, and counterimmunoelectro-
phoresis. 6 AFP was quantitated in hepatoma 
serum pool according to the method of Gitlin 
et al. 7 and used as a standard. Sera were 
assayed for AFP by radial immunodiffusion,· 
modified to increase its sensitivity. • The 
lower limit of sensitivity of this method was 
found to be approximately 1 mg per 100 mI. 
Serum concentrations of AFP between 1 mg per 
100 ml and 0.025 mg per 100 ml were measured 
by serial dilutions and by performing counter-
immunoelectrophoresis. 6 Sera were shipped 
frozen in Dry Ice and stored at -70 C until 
studied. Further details of the clinical course of 
the patients described have been published. lo 
Case 1 
Explosive tumor growth (jig. 1). A 16-year-old 
male (OT-23 IO) with primary carcinoma of the 
liver underwent total hepatectomy with ortho-
topic liver transplantation on November 10, 
1968. A very mild rejection episode in the 2nd 
week reversed with increasing the immuno-
suppressive drug dosages (see fig. 1). The pre-
operative AFP level of 78.5 mg per 100 ml fell to 
2 mg per 100 ml 11 days posttransplantation. 
The patient was discharged, apparently free of 
disease 5 weeks posttransplantation, although 
a low level of AFP persisted. Three weeks later 
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FIG. 1. Case 1, A 16-year-old male with explosive tumor growth after liver transplantation. 
the AFP level rose to 44 mg per 100 ml and sub-
sequently, progressive bilirubinemia and de-
terioration of liver function developed. The 
AFP serum concentration reached 110 mg per 
100 ml as serial liver scans demonstrated an ex-
plosive tumor growth with a rapid increase in 
liver size and increasing "cold" areas during the 
last 2 months of life. At autopsy the homograft 
liver was virtually replaced with recurrent hep-
atoma. 
Case 2 
Slow-growing tumor recurrence with chronic 
transplant rejection (jig. 2). A 16-year-old fe-
male (OT-14'O) with hepatoma underwent 
orthotopic transplantation on March 16, 1968. 
The hepatic function became abnormal over the 
1st few weeks but responded to immunosup-
pressive therapy. Subsequently, during the 
following year a chronic rejection process oc-
curred with deepening jaundice. Throughout 
this entire period the AFP level remained at 
4 to 5 mg per 100 ml. A second transplantation 
was performed after 380 days, prior to which 
metastases could not be found. At reoperation, 
there was extensive tumor involving the pos-
terior diaphragm, several ribs, the pancreas, 
and the extraperitoneal space. A very small re-
currence was present in the rejected homograft. 
The patient lived for 2 months after retrans-
plantation and finally died of carcinomatoses 
and intraperitoneal infection. In this patient, 
the prbdence of detectable AFP correctly iden-
tified the presence of recurrent tumor for al-
most 1 year before this could be proven histo-
pathologically. 
Case 3 
Moderately rapidly growing tumor recurrence 
after transient rejection (jig. 3). A 44-year-old 
male (OT-15 ' °) with hepatoma underwent 
orthotopic liver transplantation on April 14, 
1968. His AFP level of 5 mg per 100 ml fell post-
operatively to 1 to 2 mg per 100 ml. During the 
1st few weeks postoperatively, he passed 
through an acute rejection crisis with no change 
in the persistently low level of AFP. He then did 
well, apparently free of disease, for more than 
9 months with the AFP levels falling to un-
detectable amounts even though there was 
evidence by chest X-ray of pulmonary 
metastases. In the 9th postoperative month the 
AFP level rose to 4.8 mg per 100 ml just prior to 
the reappearance of jaundice, which fluctuated 
with other abnormalities of liver function. An 
area of decreased uptake on liver scan became 
evident at the hilum of the liver. Several posi-
tive blood cultures suggested liver abscess or 
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FIG. 2. Case 2, A 16-year-old female with chronic transplant rejection and slow-growing tumor recurrence. 
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FIG. 3. Case 3, A 44-year-old male with a moderately rapidly growing tumor recurrence after a transient re-
jection episode. 
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septic infarction and exploration was performed. 
At operation, although no tumor was visible in 
the liver, a needle biopsy into the suspicious 
area revealed recurrent carcinoma. At autopsy 
2 months later, a tumor 10 em in diameter was 
noted at the hilum infringing on the common 
duct and causing partial obstruction and cholan-
gitis. An even larger tumor nodule of 13 em 
diameter, which had not been suspected on 
liver scan, was found in the center of the right 
lobe. Extensive metastases were also found in 
the lungs. In this patient, the fluctuating AFP 
levels did not reflect the persistant pulmonary 
mestases noted on chest X-ray, but appeared to 
reflect the recurrent hepatic tumor. 
Case 4 
Slow growing tumor recurrence. A 1O-year-
old female (OT-26 '0) with hepatoma underwent 
orthotopic liver transplantation on May 11, 
1969. Although AFP was undetectable pre-
operatively, a low level of 2 to 3 mg per 100 ml 
was demonstrable 1 week after transplantation. 
Six weeks postoperatively, a metastasis was 
noted radiologically in the left upper lobe of the 
lung. She died of varicella infection 2 'iz months 
later, and no other metastasis was found at 
autopsy. In this patient, the persistent AFP 
level did indicate the presence of a small meta-
static focus. 
Case 5 
Possible cure. A 4-year-old female (OT-27'0) 
with biliary atresia had an orthotopic liver 
transplant on January 25, 1970. Examination of 
the excised liver unexpectedly revealed a hepa-
toma, 2 em in diameter. After transplantation 
a low level of 4 to 6 mg per 100 ml of AFP per-
sisted unchanged for about 1 month. Four 
months postoperatively AFP levels were < 0.1 
mg per ml, and after 3 more months AFP be-
came undetectable. More than 10 months post-
transplantation she is clinically well without 
signs of recurrence. 
Discussion 
a-l-Fetoprotein, an a-I globulin nor-
mally found only in fetal serum, 7 reappears 
in the serum of patients with hepatocellu-
lar carcinoma. '-6 This serum protein is 
synthesized only by embryonic liver cells 
and malignant liver cells and not by any 
other human tissue. 11 It is detectable in the 
serum of 50 to 9550 of hepatoma patients 1- 6 
depending on their ethnic origin 6 and not 
in any other benign or malignant condition, 
except in the sera of about one-third of 
children with embryonal teratoblastomas. 2 
Therefore, the presence of this fetal protein 
in adult sera has been considered to be 
diagnostic of hepatocellular carcinoma. 
The serum concentrations vary widely and 
do not appear to have any clinical signifi-
cance in any individual case. 4. 6 However, 
the level tends to stabilize or increase in the 
serum of untreated hepatoma patients, 4, 6 
falling in some patients only terminally. 6, 12 
Purves et a1. 12 reported that systemic 
chemotherapy had no significant effect on 
either the tumor or serum AFP levels. Our 
studies of patients who underwent liver 
transplantation suggest that serum AFP 
levels were apparently unaffected by im-
munosuppressive therapy, acute and chronic 
transplant rejection, or intercurrent infec-
tions (cases 1 to 4). Hepatic necrosis durin~ 
rejection episodes did not alter the AFF 
levels. This indicates that AFP is not an 
acute phase reactant, even in an AFP-
producing hepatoma. However, changes 
in the serum concentration generally 
appear to correlate with tumor growth rate, 
1S suggested by previous clinical studies 6 
md strikingly illustrated in case 1. 
Serum proteins have a rapid degrada-
tion rate after liver transplantation 10 and 
renewed synthesis reflects the donor ge-
netic pattern within days or weeks. 10, 13 
The rapid disappearance of AFP, suggest-
ing a short metabolic half-life, was illus-
trated in case 1 where serum AFP concen-
tration fell from a preoperative 78 mg per 
100 ml to 2 mg per 100 ml 11 days after 
hepatectomy. Therefore, the slow disap-
pearance of serum AFP in case 5 suggested 
that viable tumor cells persisted after trans-
plantation. The host-immune response may 
have finally destroyed the last few tumor 
cells. This patient is clinically well now, 10 
months after transplantation, and is still 
being closely followed, 
These studies strongly suggest that serial 
AFP serum levels are a helpful prognostic 
guide in assessing residual or recurrence of 
tumor after therapeutic attempts such as 
liver transplantation. 
------ --- ---
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